Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
benoxaprofen
- Development stage
- Discontinued
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Benoxaprofen is a non-steroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class, formerly used for its analgesic, antipyretic, and anti-inflammatory properties. It was primarily indicated for the treatment of rheumatoid arthritis and osteoarthritis, but also used in conditions such as psoriatic arthritis, ankylosing spondylitis, Paget's disease, polymyalgia rheumatica, back pain, and Behçet's disease. Benoxaprofen acts mainly by inhibiting arachidonate 5-lipoxygenase (lipoxygenase enzyme), thereby reducing leukotriene synthesis and monocyte chemotaxis; it is a relatively weak inhibitor of cyclooxygenase compared to other NSAIDs. The drug was withdrawn from global markets in 1982 due to reports of severe hepatotoxicity (including fatal cholestatic jaundice), nephrotoxicity, photosensitivity reactions, gastrointestinal intolerance, and other adverse effects[2][3][4][5][6].
- Brand names
- OraflexOprenCoxigonInflamid
- Other names
- BENOXAPROFEN AMMONIUM
02
Targets
PKC (Protein kinase C family)ALOX5 (Arachidonate 5-lipoxygenase)
Beyond the preview
Go deeper on benoxaprofen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on benoxaprofen.